Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 19, 2023 16:05 ET | Source: Biora Therapeutics, Inc.

Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress

SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today presented detailed results from its PM-611...
January 09, 2023 09:00 ET | Source: Biora Therapeutics, Inc.

Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023

SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced feedback from the United States...
December 30, 2022 09:00 ET | Source: Biora Therapeutics, Inc.

Biora Therapeutics Announces Reverse Stock Split

SAN DIEGO, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will effect a reverse stock...
December 08, 2022 16:05 ET | Source: Biora Therapeutics, Inc.

Biora Therapeutics Announces Two Poster Presentations at the Crohn’s & Colitis Congress

SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced acceptance of two abstracts...
November 29, 2022 09:00 ET | Source: Biora Therapeutics, Inc.

Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial Development

SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it has completed an agreement to...
November 14, 2022 16:01 ET | Source: Biora Therapeutics, Inc.

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Presented results of human study at the American College of Gastroenterology annual meeting, demonstrating promising device performance in active ulcerative colitis patients Executed a...
November 07, 2022 16:15 ET | Source: Biora Therapeutics, Inc.

Biora Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update

SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report third quarter...
November 07, 2022 08:06 ET | Source: Biora Therapeutics, Inc.

Biora Therapeutics Announces $9.75 Million Direct Offering

SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into a...
October 27, 2022 09:00 ET | Source: Biora Therapeutics, Inc.

Biora Therapeutics Announces Sale of Cell-Free DNA Patent Rights

SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it has completed a one-time asset...
October 25, 2022 09:00 ET | Source: Biora Therapeutics, Inc.

Biora Therapeutics Shares Data from Device Performance Study in Ulcerative Colitis Patients

SAN DIEGO, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today presented detailed results from its PM-602...